NCT05219578
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy, Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients with BRCA1/2 mutations should have previously received or been ineligible for an approved PARP inhibitor (e.g. Lynparza/olaparib, Talzenna/talazoparib); Patients who have cancers that are PD-L1+ should have received or been ineligible for an approved PD-1 or PD-L1 inhibitor (e.g. Keytruda/pembrolizumab, Tecentriq/atezolizumab)
Exclusions: Patients with symptomatic, unstable, untreated brain metastases- see trial for details
https://ClinicalTrials.gov/show/NCT05219578